CA2867481A1 - Tuberculosis biomarkers and uses thereof - Google Patents

Tuberculosis biomarkers and uses thereof Download PDF

Info

Publication number
CA2867481A1
CA2867481A1 CA2867481A CA2867481A CA2867481A1 CA 2867481 A1 CA2867481 A1 CA 2867481A1 CA 2867481 A CA2867481 A CA 2867481A CA 2867481 A CA2867481 A CA 2867481A CA 2867481 A1 CA2867481 A1 CA 2867481A1
Authority
CA
Canada
Prior art keywords
biomarker
individual
biomarkers
biological sample
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2867481A
Other languages
English (en)
French (fr)
Inventor
Urs Ochsner
David G. STERLING
Nebojsa Janjic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Inc
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of CA2867481A1 publication Critical patent/CA2867481A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2867481A 2012-04-13 2013-04-12 Tuberculosis biomarkers and uses thereof Abandoned CA2867481A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623732P 2012-04-13 2012-04-13
US61/623,732 2012-04-13
PCT/US2013/036447 WO2013155460A1 (en) 2012-04-13 2013-04-12 Tuberculosis biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
CA2867481A1 true CA2867481A1 (en) 2013-10-17

Family

ID=49328218

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2867481A Abandoned CA2867481A1 (en) 2012-04-13 2013-04-12 Tuberculosis biomarkers and uses thereof

Country Status (6)

Country Link
US (3) US20140155411A1 (https=)
EP (1) EP2836608A4 (https=)
JP (1) JP2015514227A (https=)
CA (1) CA2867481A1 (https=)
HK (1) HK1205764A1 (https=)
WO (1) WO2013155460A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836608A4 (en) 2012-04-13 2016-02-24 Somalogic Inc TUBERCULOSIS BIOMARKERS AND USES THEREOF
WO2015164616A1 (en) * 2014-04-24 2015-10-29 Somalogic, Inc. Biomarkers for detection of tuberculosis
US20180356419A1 (en) * 2015-05-08 2018-12-13 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
GB201519872D0 (en) 2015-11-11 2015-12-23 Univ Cape Town And Ct For Infectious Disease Res Biomarkers for prospective determination of risk for development of active tuberculosis
GB201602305D0 (en) * 2016-02-09 2016-03-23 Medical Res Council And Imp Innovations Ltd TB Biomarkers
WO2017179008A1 (en) * 2016-04-15 2017-10-19 Stellenbosch University Host biomarkers for immunodiagnosis and monitoring of tuberculosis disease
US10607228B1 (en) * 2016-08-24 2020-03-31 Jpmorgan Chase Bank, N.A. Dynamic rule strategy and fraud detection system and method
EP3536803A4 (en) * 2016-11-02 2020-07-15 Biois Co., Ltd. METHOD FOR QUANTITATIVE CLUSTER ANALYSIS OF THE TARGET PROTEIN BY SEQUENCING THE NEXT GENERATION AND USE THEREOF
US20190392952A1 (en) * 2016-12-09 2019-12-26 Basil Leaf Technologies, Llc Computer-implemented methods, systems, and computer-readable media for diagnosing a condition
JP6812789B2 (ja) * 2016-12-28 2021-01-13 富士通株式会社 情報処理装置、情報処理プログラム、および情報処理方法
WO2019202448A1 (en) * 2018-04-16 2019-10-24 University Of Cape Town A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis
WO2020162441A1 (ja) * 2019-02-04 2020-08-13 国立大学法人大阪大学 肉芽腫性疾患バイオマーカー
WO2021064592A1 (en) * 2019-09-30 2021-04-08 University Of Cape Town Method for diagnosing tuberculosis in urine samples
CN112034176B (zh) * 2020-07-09 2022-08-30 中国工程物理研究院材料研究所 Cntn1作为长期低剂量电离辐射暴露诊断的分子标记物的用途
US20220026417A1 (en) * 2020-07-21 2022-01-27 Industry-University Cooperation Foundation, Catholic University of Pusan Method of simultaneously diagnosing active tuberculosis and latent tuberculosis infection using human whole blood sample-derived biomarker
CN112481369A (zh) * 2020-12-03 2021-03-12 中国医学科学院病原生物学研究所 Msrb1作为结核病诊断分子标识的用途
US11676726B2 (en) * 2021-06-22 2023-06-13 David Haase Apparatus and method for generating a treatment plan for salutogenesis
WO2023021262A1 (en) * 2021-08-17 2023-02-23 Scotland's Rural College Methods of determining animal phenotypes
CZ309154B6 (cs) * 2021-08-20 2022-03-16 GeneSpector Innovations s.r.o. Způsob predikce závažnosti průběhu infekčního onemocnění a biomarker pro použití při provádění tohoto způsobu a monitoringu terapie infekčního onemocnění
CN114250310B (zh) * 2021-11-15 2023-12-08 四川大学华西医院 用于检测结核病的dna甲基化标志物、诊断模型、甲基化探针及试剂盒
CN115466797A (zh) * 2022-06-06 2022-12-13 四川大学华西第二医院 用于检测rs4770965和rs9507713的试剂在制备结核筛查试剂盒中的用途
US20240229138A9 (en) * 2022-10-24 2024-07-11 Inflammatix, Inc. Fluidic device and methods for characterization of an infection or other condition
CN116106556B (zh) * 2022-12-29 2026-04-03 梅州市人民医院(梅州市医学科学院) 一种量子点荧光微球定量检测胎球蛋白b的免疫层析试纸条及其制备方法
EP4467662A1 (en) * 2023-05-26 2024-11-27 Forschungszentrum Borstel, Leibniz Lungenzentrum Method for predicting the time point of culture conversion in individuals
CN119689002B (zh) * 2025-02-25 2025-06-06 山东大学 用于预测胚胎反复种植失败的生物标志物组合、试剂盒及其应用和联合药物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143506A (en) * 1998-08-13 2000-11-07 The Research Foundation Of State Of Ny Diagnostic method for detection of periodontitis or peri-implantitis
AU2003241055A1 (en) * 2002-06-20 2004-01-06 Glaxo Group Limited Surrogate markers for the determination of the disease status of an individual infected by mycobacterium tuberculosis
US20060009378A1 (en) * 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
ZA200510325B (en) * 2003-06-13 2008-04-30 Univ Pittsburgh Monitoring immunologic, hematologic and inflammatory diseases
GB0510511D0 (en) * 2005-05-23 2005-06-29 St Georges Entpr Ltd Diagnosis of tuberculosis
JP2007024631A (ja) 2005-07-14 2007-02-01 Human Science Shinko Zaidan 同位体標識法
ATE500275T1 (de) * 2005-09-26 2011-03-15 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
WO2007103770A2 (en) * 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
KR100961926B1 (ko) * 2007-08-30 2010-06-10 서울대학교산학협력단 당뇨병성 망막병증 검출용 바이오 마커 조성물 및 진단키트
AT505727B1 (de) * 2007-09-04 2009-06-15 Univ Innsbruck Verfahren zur diagnose des metabolischen syndroms
AP2011005546A0 (en) * 2008-06-25 2011-02-28 Baylor Res Intitute Blood transcriptional signature of mycobacterium tuberculosis infection.
US20110129817A1 (en) * 2009-11-30 2011-06-02 Baylor Research Institute Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
US8889364B2 (en) * 2009-05-14 2014-11-18 The Chancellor, Masters And Scholars Of The University Of Oxford Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
JP2013523117A (ja) * 2010-03-31 2013-06-17 フイルメニツヒ ソシエテ アノニム フレーバーを含んでなる中実カプセルの製造
EP3345915B1 (en) * 2010-04-12 2021-11-24 Somalogic, Inc. 5-position modified pyrimidines and their use
EP2836608A4 (en) 2012-04-13 2016-02-24 Somalogic Inc TUBERCULOSIS BIOMARKERS AND USES THEREOF
CN103065065A (zh) * 2012-11-18 2013-04-24 浙江大学 一种活动性肺结核蛋白表达差异质谱模型及构建方法

Also Published As

Publication number Publication date
US20180128839A1 (en) 2018-05-10
JP2015514227A (ja) 2015-05-18
EP2836608A4 (en) 2016-02-24
EP2836608A1 (en) 2015-02-18
HK1205764A1 (en) 2015-12-24
WO2013155460A1 (en) 2013-10-17
US10408847B2 (en) 2019-09-10
US20160109462A1 (en) 2016-04-21
US20140155411A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
US10408847B2 (en) Tuberculosis biomarkers and uses thereof
CA2734535C (en) Lung cancer biomarkers and uses thereof
CN104777313B (zh) 肺癌生物标记及其用途
AU2011289284B2 (en) Pancreatic cancer biomarkers and uses thereof
US10359425B2 (en) Lung cancer biomarkers and uses thereof
CN107422126B (zh) 心血管危险事件预测及其用途
AU2011378427B8 (en) Lung cancer biomarkers and uses thereof
KR102087373B1 (ko) 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법
CA2843756A1 (en) Renal cell carcinoma biomarkers and uses thereof
HK40073398A (en) Cardiovascular risk event prediction and uses thereof
HK1229003B (zh) 胰腺癌生物标记及其用途
HK1236619A1 (en) Cardiovascular risk event prediction and uses thereof
HK1153834B (en) Lung cancer biomarkers and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180410

FZDE Discontinued

Effective date: 20200831